)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Apellis Pharmaceuticals (APLS) investor relations material
Apellis Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary30 Oct, 2025
Executive summary
Achieved FDA approval for EMPAVELI in C3G and primary IC-MPGN, expanding the addressable market and marking a significant milestone in rare kidney disease treatment.
Q3 2025 net income reached $215.7 million, reversing a prior year net loss, primarily due to a $275 million upfront payment from Sobi under a new royalty agreement.
Total Q3 2025 revenue was $458.6 million, driven by licensing and product sales, with SYFOVRE and EMPAVELI as key contributors.
SYFOVRE maintained leadership in the geographic atrophy market, with over 60% market share and 52% of new patient starts, despite only 10% of GA patients currently treated.
EMPAVELI launch in C3G and IC-MPGN saw strong early adoption, with 152 patient start forms and positive feedback from nephrologists.
Financial highlights
Total Q3 2025 revenue was $458.6 million, up from $196.8 million in Q3 2024.
Net income for Q3 2025 was $215.7 million, compared to a net loss of $57.4 million in Q3 2024.
SYFOVRE U.S. net product revenue was $150.9 million; EMPAVELI U.S. net product revenue was $26.8 million.
Licensing and other revenue surged to $280.8 million, driven by the Sobi agreement.
Operating expenses decreased to $235.4 million from $244.1 million year-over-year.
Outlook and guidance
Cash and cash equivalents of $479 million as of September 30, 2025, expected to fund operations to profitability.
Modest SYFOVRE injection growth expected in Q4, with revenue broadly in line with Q3.
Two pivotal studies in FSGS and DGF are planned to initiate by year-end 2025.
Full-year operating expenses expected to align with 2024 levels.
Cash position sufficient to fund business to sustainable profitability.
EMPAVELI C3G/IC-MPGN patient conversion outlook?
When will SYFOVRE free goods utilization normalize?
Sobi royalty deal: long-term ex-U.S. revenue impact?
SYFOVRE: Key initiatives to reaccelerate growth?
EMPAVELI C3G/IC-MPGN: post-initial bolus growth?
EMPAVELI: Strategic rationale for FSGS/DGF trials?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Apellis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
Next Apellis Pharmaceuticals earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Apellis Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for autoimmune and rare diseases. The company’s research is centered around complement inhibition, targeting the C3 protein in the complement system, which plays a key role in immune response. Apellis’ lead products and drug candidates aim to treat conditions such as geographic atrophy (a form of age-related macular degeneration) and paroxysmal nocturnal hemoglobinuria (PNH), among other serious diseases. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage